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Abstract 
MiRNAs are post-transcriptional regulators of protein expression and are believed to play a 
role in the failure of β-cells to secrete sufficient insulin to maintain glucose homeostasis, thus 
leading to type 2 diabetes mellitus. Syntaxin1a (STX1A), a t-SNARE protein involved in insulin 
exocytosis, has been reported down-regulated in response to prolonged exposure to high 
glucose levels (Dubois et al., 2007). Deregulation of STX1A has been connected with an 
impaired insulin exocytosis (Ohara-Imaizumi et al., 2007). Unpublished data from a research 
group at Roskilde University show that miR-29a is glucose induced in the INS-1E β-cell line 
from rats. Databases predict a miR-29a target site in the 3’ UTR of Stx1a. Dual luciferase 
assays using INS-1E cells with varying glucose concentrations is performed to test the 
hypothesis that miR-29a is a mediator of STX1A down-regulation due to high glucose levels. 
There is an insufficient amount of data to conclude whether there is a significant interaction 
between miR-29a and the predicted target site from Stx1a. Nevertheless the data indicates a 
tendency of a slight regulation of STX1A by miR-29a. It could not be confirmed that miR-29a is 
glucose induced. Furthermore the data suggests that the used dual luciferase assay is 
unreliable under high glucose levels in INS-1E cells. 
  
Table of Contents 
1 INTRODUCTION ................................................................................................................................................. 4 
1.1 INSULIN EXOCYTOSIS IS DISTURBED BY DEREGULATION OF STX1A ........................................................................................ 5 
1.1.1 Insulin exocytosis has two phases ............................................................................................................... 5 
1.1.2 STX1A has two distinct functions in exocytosis ........................................................................................... 5 
1.2 MIRNAS ARE POST-TRANSCRIPTIONAL REGULATORS AND MIGHT PLAY A ROLE IN Β-CELL DYSFUNCTION ...................................... 7 
1.2.1 Biogenesis of miRNAs ................................................................................................................................. 7 
1.2.2 Mode of action of miRNAs .......................................................................................................................... 9 
1.2.3 MiRNAs in T2DM ....................................................................................................................................... 10 
1.3 STX1A CONTAINS A PREDICTED TARGET OF MIR29-A ...................................................................................................... 10 
2 METHODS .........................................................................................................................................................13 
2.1 PREPARATION OF VECTORS ........................................................................................................................................ 13 
2.1.1 DNA-oligos ................................................................................................................................................ 13 
2.1.2 Digestion of pGL4.13 ................................................................................................................................. 13 
2.1.3 Preparation of agarose gel ....................................................................................................................... 14 
2.1.4 Gel electrophoresis for purification of digested pGL4.13 .......................................................................... 14 
2.1.5 Purification of digested vector .................................................................................................................. 14 
2.1.6 Annealing of DNA-oligos ........................................................................................................................... 14 
2.1.7 Phosphorylation of DNA oligos ................................................................................................................. 15 
2.1.8 Ligation of DNA oligos and pGL4.13 ......................................................................................................... 15 
2.1.9 Preparation of LB media and E. coli .......................................................................................................... 15 
2.1.10 Transformation .................................................................................................................................... 15 
2.1.11 Minipreps for restriction analysis ......................................................................................................... 16 
2.1.12 Restriction analysis ............................................................................................................................... 16 
2.1.13 Midiprep ............................................................................................................................................... 17 
2.1.14 Sequencing ........................................................................................................................................... 17 
2.2 GROWTH OF INS-1E................................................................................................................................................ 17 
2.3 DUAL LUCIFERASE ASSAY ........................................................................................................................................... 19 
2.3.1 RNA/LNA oligos ......................................................................................................................................... 19 
2.3.2 Transfection with 11 mM glucose ............................................................................................................. 19 
2.3.3 Transfection with 5 mM and 20 mM glucose ........................................................................................... 19 
2.3.4 Transfection with RNA oligos and DNA at 11 mM glucose ....................................................................... 20 
2.3.5 Measurements of luciferase activity ......................................................................................................... 20 
 
  
3 RESULTS ...........................................................................................................................................................21 
3.1 PREPARATION OF CONSTRUCTS ................................................................................................................................... 22 
3.1.1 Design and Cloning of DNA-oligos ............................................................................................................ 22 
3.1.2 Restriction analysis ................................................................................................................................... 24 
3.1.3 Sequence analysis ..................................................................................................................................... 28 
3.2 DUAL LUCIFERASE ASSAY ........................................................................................................................................... 34 
3.2.1 FF is slightly down-regulated due to having the miR-29a target site of Stx1a in the 3‘UTR ..................... 35 
3.2.2 Varying glucose levels have no impact on miR-29a expression in the dual luciferase assay .................... 38 
3.2.3 Failed dual-luciferase assay with cotransfection of RNA/LNA-oligos ....................................................... 39 
4 DISCUSSION ......................................................................................................................................................41 
5 CONCLUSION ....................................................................................................................................................43 
6 CONSIDERATIONS FOR FURTHER RESEARCH .....................................................................................................44 
7 REFERENCES .....................................................................................................................................................46 
8 APPENDIX ........................................................................................................................................................... I 
8.1 PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS........................................................................................................... I 
8.1.1 Pathogenesis of Type 2 Diabetes Mellitus ................................................................................................... I 
8.1.2 The Role of Insulin Secretion in Type 2 Diabetes Mellitus ............................................................................ I 
8.2 GFP-TRANSFECTION OF INS-1E CELLS .......................................................................................................................... IV 
8.2.1 Method....................................................................................................................................................... IV 
Varied amount of GFP ............................................................................................................................................ IV 
Varied amount of LF2000 .......................................................................................................................................... V 
8.2.2 Results ......................................................................................................................................................... V 
8.3 PGL4.13 ................................................................................................................................................................ IX 
8.4 STATISTICAL TEST ..................................................................................................................................................... XI 
 
 4 | P a g e  
 
Introduction 
1 Introduction 
Type 2 diabetes mellitus (T2DM) is one of the most widespread disorders worldwide. In 
Denmark alone at least 200,000 was diagnosed with T2DM in 2005 (Sundhedsstyrelsen, 
2005) and in 2007 the number had risen to 240,358 (Sundhedsstyrelsen, 2009), which 
reflects that it is a growing disease in the Western world and justifies calling T2DM an 
epidemic. The disorder is the result of the complex interplay between multiple factors, 
including genetic predisposition, obesity and physical inactivity. T2DM affects almost all 
tissues and organs and may finally lead to complications as different and severe as renal 
failure, blindness, slow healing wounds and arterial diseases (reviewed in Lin & Sun, 2010). 
Obviously, it is important to fully elucidate the molecular background for this metabolic 
disorder. In this project it is examined whether syntaxin-1a (STX1A), a protein involved in 
insulin exocytosis from pancreatic β-cells, is regulated by miR-29a, a glucose induced 
microRNA (miRNA). A decreased translation of STX1A due to an up-regulation of miR-29a 
might have an impact on insulin secretion and hence play a role in T2DM. 
 
The pathophysiology of T2DM is accounted for in Appendix  8.1. From that discussion it is 
evident that impaired insulin secretion is one of the critical biological processes for the onset 
of T2DM. It is not only decreased β-cell mass due to apoptosis, but also β-cell dysfunction 
probably contributes to impaired insulin secretion from pancreatic β-cells in T2DM (reviewed 
in Chang-Chen, Mullur, & Bernal-Mizrachi, 2008). 
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1.1 Insulin exocytosis is disturbed by deregulation of STX1A 
A dysfunctional insulin exocytosis might contribute to an impaired insulin secretion. Here an 
introduction is given to the mechanism behind insulin exocytosis and the role of STX1A in this 
pathway. 
1.1.1 Insulin exocytosis has two phases 
Insulin exocytosis is the process of releasing granules containing insulin from pancreatic β-
cells. The secretion of insulin is stimulated by glucose and is shown to be biphasic (Rorsman 
et al., 2000). The two phases are distinguished by the timing of granule excretion. The first 
phase is an immediate secretion of insulin, where the second phase is a consistent and slower 
release. The first phase secretes insulin vesicles from a pool of granules called ready 
releasable pool of granules (RRP). These granules are already docked to the plasma 
membrane of β-cells. The second phase utilizes granules from the reserve pool, which is 
located further away from the release sites. Over 95% of the granules are in the reserve pool 
and needs to be mobilized by chemical modification or physical translocation to enter the RRP 
(Rorsman et al., 2000). 
1.1.2 STX1A has two distinct functions in exocytosis 
There are several important factors involved in the exocytosis of granules. Fusion of the 
granules in the RRP with the β-cell plasma membrane is handled by soluble N-
ethylmaleimide-sensitive factor attachment protein receptor complexes (SNAREs). The 
vesicle SNARE (v-SNARE) protein synaptobrevin interacts with the plasma membrane target-
SNARE (t-SNARE) proteins SNAP-25 and STX1A and forms a SNARE complex with a non-
locked conformation that juxtaposes the two membranes. When the SNARE complex is in this 
conformation Ca2+ influx triggers a change of the SNARE complex to another conformation, in 
which the two protein complexes are interlocked (reviewed in Hong, 2005).  
STX1A is not only directly involved in the exocytosis, but also plays a role as a regulator of 
Ca2+ concentration by closing voltage-dependent Ca2+ channels (VDCCs)(Bezprozvanny, 
Zhong, Scheller, & Tsien, 2000). VDCCs controls the Ca2+ level of the β-cell required to activate 
exocytosis (Ashcroft et al., 1994). Is has been shown that STX1A is located physically near the 
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VDCCs and that it has two binding sites, where one is for anchoring and one is modulatory 
(Bezprozvanny et al., 2000). This study also finds that the subunit of STX1A involved in the 
modulatory effect, is only exposed after vesicle exocytosis and SNARE complex disassembly. 
The modulatory mechanism is not known, but it supports a slow inactivation of VDCC 
(Degtiar, Scheller, & Tsien, 2000).These findings suggest that STX1A acts on two levels of 
insulin exocytosis. It can be hypothesized that when the Ca2+ level increases in the cell, STX1A 
first fuses the membranes of the vesicles in the RRP with the plasma membrane, after which it 
disassembles and is free to bind to the VDCCs to inhibit further Ca2+ influx – thus acting as 
negative feedback mechanism on the exocytosis.  
An experiment where STX1A was overexpressed showed a 50 % decrease in glucose 
stimulated insulin release (Nagamatsu et al., 1996). The exact mechanisms linking STX1A 
functions to the separate phases of exocytosis is still unknown, but one study indicates that 
knockdown of STX1A induced a significant inhibition of the first phase of exocytosis, but left 
the second phase intact (Ohara-Imaizumi et al., 2007). Another in vitro experiment where 
STX1A were overexpressed showed no alterations in the Ca2+ concentration or in glucose 
metabolism of the β-cells investigated (Nagamatsu, Nakamichi, Yamaguchi, Sawa, & Akagawa, 
1997). This suggests that STX1A’s function might only be prominent in the late steps of insulin 
exocytosis and might need additional factors to enable inhibition. Dubois et al. (2007) found 
that STX1A among other proteins involved in the late steps of insulin exocytosis were down-
regulated in INS-1E cells in response to 72 h exposure to high glucose levels (20 mM or 30 
mM) (Dubois et al., 2007). This finding establishes a connection between high glucose levels 
and a disturbance of insulin exocytosis, which might affect the total insulin secretion.  
Previous studies give a complex picture on the effects of deregulating STX1A, where both up- 
and down-regulation of STX1A were shown to have some effect on insulin exocytosis. Hence a 
tight regulation of STX1A might be important to maintain effective insulin exocytosis. 
Furthermore a high glucose level is a possible cause for the deregulation of STX1A. 
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1.2 MiRNAs are post-transcriptional regulators and might play a role in β-cell 
dysfunction 
There is some evidence that miRNAs have a role in development of T2DM (reviewed in Tang, 
Tang, & Ozcan, 2008). Biogenesis, mode of action and regulation pathways of miRNA will be 
discussed in this section, before some recent advances in the research of miRNAs in β-cells are 
presented. 
A decade ago, the discovery of a post-transcriptional silencing process drew attention to small 
RNA molecules; extensive research has suggested that miRNAs play a role in protein 
expression regulation and thereby in determination of cell fate (reviewed in Shalgi, Brosh, 
Oren, Pilpel, & Rotter, 2009). MiRNAs are 16-29 nucleotides (nt), usually 21-23 nt, long non-
coding RNAs and either cause degradation or block translation of their target mRNAs 
(reviewed in Erson & Petty, 2008). Approximately 30 % of mRNAs are predicted to be 
targeted by miRNAs (reviewed in Filipowicz, Bhattacharyya, & Sonenberg, 2008), where each 
mRNA is predicted to be regulated by several miRNAs, which each may bind up to several 
hundred mRNAs (Baek et al., 2008). 
1.2.1 Biogenesis of miRNAs 
MiRNAs originate from different kind of genes. Some are in clusters of two to seven genes, 
some are expressed individually as a part of non-coding genes, and others are excised from 
introns or the 3´-untranslated regions (UTRs) from protein-coding mRNAs (reviewed in 
Mendes, Freitas, & Sagot, 2009). The co-expression of several miRNAs or of a miRNA with a 
protein suggests that they may be part of a common biological process. Most miRNA genes are 
transcribed by the highly regulated RNA polymerase II (Cai, Hagedorn, & Cullen, 2004), 
whereas a few might depend on RNA polymerase III (Borchert, Lanier, & Davidson, 2006). 
Indeed, miRNAs seem to be primarily controlled at the level of transcription, but there is some 
evidence of post-transcriptional regulation discussed later.  
In animal cells the maturation of the primary transcript of the gene, called primary miRNA 
(pri-miRNA), to the mature form, miRNA, is a two-step process. The first step occurs in the 
nucleus and the second in the cytoplasm, see Figure 1. Pri-miRNAs contain a stem-loop, also 
known as a hairpin (reviewed in Cullen, 2004). The Drosha enzyme cleaves the several 
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hundred nt pri-miRNA into an approximately 70 nt precursor miRNA (pre-miRNA), 
containing the hairpin. The pre-miRNA is protected against exonucleases and transported out 
of the nucleus by Exportin 5 (Lund, Guttinger, Calado, Dahlberg, & Kutay, 2004). 
 
Figure 1: The pri-miRNA is processed by the endonuclease Drosha in the nucleus. The resulting pre-miRNA has 
a hairpin structure and is transported to the cytoplasm by Exportin 5. Further cleavage is performed by 
another endonuclease, Dicer. Usually only one strand, miRNA, of the miRNA/miRNA* duplex is a part of RISC 
assembly. Edited from (Tomari & Zamore, 2005). 
In the cytoplasm pre-miRNAs are processed by Dicer, another RNase III, into an 
approximately 22 nt double-stranded miRNA:miRNA* (Hutvagner & Zamore, 2002). These 
double-stranded miRNAs readily unwind due to mismatches or bulges (not illustrated in 
Figure 1) and, usually, one of the two strands, miRNA, is taking part in the formation of the 
RNA induced silencing complex (RISC), while the other, miRNA*, is degraded (Khvorova, 
Reynolds, & Jayasena, 2003). RISC contains an argonaute protein, which has endonuclease 
activity and is thought to be a main component of RISC (Rand, Petersen, Du, & Wang, 2005). 
The amount of miRNA present in a cell is determined by their production and degradation. As 
mentioned previously they are regulated at the level of transcription. Little is known about 
additional regulatory mechanisms. Nevertheless there are indications of the existence of 
posttranscriptional regulation (Ambros, Lee, Lavanway, Williams, & Jewell, 2003). Cases of 
RNA editing of miRNAs are known (reviewed in Erson & Petty, 2008). Furthermore miRNAs 
might bind regions in other non-coding RNAs thereby establishing a negative regulation of 
miRNA activity (Chitwood & Timmermans, 2007). A recent study proposes that the presence 
of target RNAs enhances the stability of miRNAs (Chatterjee & Grosshans, 2009). 
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1.2.2 Mode of action of miRNAs 
MiRNAs are partially complementary and normally bind to sequences in the 3´ UTRs of mRNA, 
though basepairing to exons or 5´ UTRs also occur (reviewed in Mendes et al., 2009). As 
mentioned above, miRNAs primarily exert their function in one of two ways on target mRNAs.  
In animals the main pathway of miRNAs is blocking the translation of the target mRNAs and 
thereby reducing protein formation (Lai, 2002). In addition to the main inhibitory pathways it 
is proposed that some miRNAs even might have a positive regulatory role by promoting either 
transcription by binding to promoter regions (Place, Li, Pookot, Noonan, & Dahiya, 2008) or 
translation by an unknown mechanism (Vasudevan, Tong, & Steitz, 2007). Potentially, 
miRNAs are capable of binding all kinds of RNA. 
The relative importance of the different determinants of miRNA target recognition is an issue 
of debate. A perfect match of the seed sequence seems to be critical for miRNAs to 
discriminate between mRNAs. This is an approximately 7 nt sequence, extending from 
position 2 to 8 on the 5´end of the miRNA (Lewis, Shih, Jones-Rhoades, Bartel, & Burge, 2003). 
However, miRNAs do not target all mRNAs in which the seed sequence matches and some 
mRNAs are targeted despite of an imperfect seed match (Grimson et al., 2007). Other features 
that may have some relevance for the binding is additional complementarity of miRNA and 
target site, the A- and U-content of the target site and its flanking regions, the structural 
accessibility and position of the putative site and whether several target sites for different 
miRNAs exists in close proximity (Hausser, Landthaler, Jaskiewicz, Gaidatzis, & Zavolan, 
2009). It is beyond the scope of this project to discuss the relative relevance of the different 
determinants in detail. 
MiRNAs are believed to be a fine-tuning mechanism of protein expression, as translation of 
target mRNAs is merely slightly inhibited (Baek et al., 2008). One could be puzzled by this 
finding as there is an obvious discrepancy between a fine-tuning mechanism and the notion of 
miRNAs being essential determinants of cell fate. Shalgi et al. (2009) have proposed two 
models to overcome this conceptual gap. They argue that miRNAs might be able to down-
regulate several proteins in one pathway and amplify the impact. This might be because one 
miRNA has multiple targets and/or that miRNAs could function cooperatively with other 
miRNAs, especially if they are from the same family. Additionally it is proposed that miRNAs 
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are a part of regulating networks with transcriptions factors (TF). Together a TF and a miRNA 
constitute Feedforward Loops (FFL), where either one TF regulates transcription of both a 
miRNA and the targets of the miRNA or where one miRNA is regulating both a TF and the 
targets of the TF. FFL might also contribute to avoid that miRNAs and their targets are 
expressed at the same time (reviewed in Shalgi et al., 2009). 
1.2.3 MiRNAs in T2DM 
Poy et al. (2007) and Tang et al. (2008) review the role of miRNAs in T2DM. Various miRNAs 
might regulate relevant proteins in muscle, liver, adpocyte and/or pancreas. E.g. loss- and 
gain-of-function studies show that deregulation of miR-375 influence insulin secretion in β-
cells due to a negative effect on insulin exocytosis (Poy et al., 2004). Moreover miR-9 and miR-
124a2 might be involved in the negative regulation of insulin secretion and in the 
differentiation of β-cells, respectively (Baroukh et al., 2007; Plaisance et al., 2006). These 
three miRNAs might be involved in pathophysiology of the disease, when they are deregulated 
at some point in the course of T2DM. Potentially miRNAs even constitute targets for 
pharmacological treatment of T2DM. 
Another approach in the search for pathogenic miRNAs is to consider the miRNAs which are 
regulated by symptoms of diseases. For instance miR-34a and miR-146 are up-regulated in β-
cells by high fatty acid concentrations, making these miRNAs candidates for conveying 
lipotoxicity (Lovis et al., 2008). 
1.3 Stx1a contains a predicted target of miR29-a 
In the search for other miRNAs relevant in T2DM, the highly conserved miR-29 family, 
containing miR-29a-c, seems to be of interest. In muscle, fat and liver from diabetic Goto-
Kakazaki rats compared to healthy rats, miR-29a, miR29b and miR-29c has been found up-
regulated approximately 1.5, 1.7 and 1.7 times, respectively (He, Zhu, Gupta, Chang, & Fang, 
2007). In the same study in vitro assays showed, that up-regulation of miR-29a and miR-29b 
were induced by hyperinsulinemia and hyperglycemia in 3T3-L1 adipocytes. It should be 
noted that targeted proteins might be regulated by several members of the miR-29 family as 
they have identical seed sequences and only contain minor variations, see Table 1. Since the 
increased expression of miR-29 is found to decrease insulin sensitivity in muscles, 
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hepatocytes and adipocytes, this pathway is suggested to constitute a negative feedback 
mechanism for insulin (He et al., 2007). However there might be other determining factors 
than glucose and insulin levels, as hyperinsulinemia and hyperglycemia could not account for 
the up-regulation of miR-29c. In accordance with these results another study finds a 1.5 times 
higher concentration of miR-29a in the adipose tissue of Goto-Kakizaki rats (Herrera et al., 
2009). 
MiR-29a and miR-29b1 as well as miR-29b2 and miR-29c are located in close proximity on 
chromosome 4 and 13, respectively, and the transcription of the two pairs might be coupled 
(He et al., 2007). 
MiR-29 might possibly be linked to T2DM through another pathway, if the miRNA family or 
one of its members regulates the predicted target in Stx1a. The MiR-29 family is expressed in 
pancreatic β-cells (Landgraf et al., 2007). Unpublished data from the research group in 
diabetes and β-cell biology at Roskilde University shows that miR-29a is expressed strongly in 
INS-1E cells, a cell line from pancreatic β-cells of rats. Furthermore the unpublished data from 
the same laboratory shows that miR-29a is glucose induced in INS-1E cells after 24-48 hours. 
Therefore the focus is on miR-29a in this project. There is no divergence between the 
sequences of miR-29a in rats and humans. 
There are several databases for prediction of miRNA targets available, using different 
algorithms to predict targets, which results in variations from one database algorithm to 
another. The list of predicted regulators of STX1A obtained from the PicTar algorithm 
contains miR-29b and miR-29c, but not miR-29a (PicTar, 2009). Nevertheless Stx1a is a 
predicted target of the entire miR-29 family by the Targetscan and Microcosm Targets 
algorithm (Microcosm, 2009a; Targetscan, 2009). The sequence of the predicted target site 
and of all members of the miR-29 family is shown in Table 1. The three bases at position 9, 11 
and 13 on the miRNAs are also able to base-pair with the target site on Stx1a of rats. 
Additionally miR-29b matches the target site at position 21 and 22 probably contributing to a 
stronger binding. The human target site on STX1A might be weaker due to a C instead of a U in 
the target site, corresponding to one fewer possibility to base-pair with the A at position 13 of 
miRNAs. 
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MiRNA Sequences 
422-444 of human STX1A 3' UTR 5‘  ...GACCAGCUGGCCACAUGGUGCUG... 
437-459 of rat Stx1a 3' UTR 5‘  ...GACCAGCUGGUCACAUGGUGCUG... 
MiR-29a 3’        AUUGGCUAAAGUCUACCACGAU 
MiR-29b1/ miR-29b2 3’     UUGUGACUAAAGUUUACCACGAU 
MiR-29c 3’        AUUGGCUAAAGUUUACCACGAU 
Table 1: Predicted antisense pairing of the miR-29 family and target sites on 3´UTR of STX1A from 
human and rat. The seed sequence is shown in bold text. Irregularities in the sequences of the 
miRNAs are underlined and the difference in human and rat target site is colored green. (Targetscan, 
2009) 
MiR-29a has a multitude of confirmed targets. 326 to 1117 targets are predicted depending 
on the database used (Microcosm, 2009b; PicTar, 2009). MiR-29a is included in a wide variety 
of functions, e.g. miR-29a is a regulator of cardiac fibrosis (van Rooij et al., 2008) and it is said 
to act as a tumor suppressor (Wang et al., 2008) and an oncogene under different 
circumstances (Gebeshuber, Zatloukal, & Martinez, 2009). Considering the various roles of 
merely this miRNA, it is not difficult to imagine the impact of these small posttranscriptionally 
silencing molecules on cellular processes. Though miR-29a only is found up-regulated 1.5 fold 
in some tissues of diabetic rats, it might still have an impact on protein expression due to the 
targeting of diverse proteins in a pathway.  
Summarizing the introduction, the pathways of the pathophysiology in the multifactorial and 
complex disease T2DM is still not fully understood. The ubiquitous miRNAs are recently found 
to be connected to T2DM. Since miR-29a is shown to be up-regulated by glucose after 24-48 
hours in β-cells according to unpublished data, and since it has a predicted target site in Stx1a, 
it is an interesting subject for investigation. At the same time STX1A is shown to be down-
regulated through prolonged exposure (72 h) to hyperglycemia (20 mM or 30 mM glucose) 
(Dubois et al., 2007). MiR-29a might be the mediator causing the down-regulation of STX1A in 
response to high glucose levels. Moreover deregulation of STX1A is found to disturb insulin 
exocytosis and hence might be connected to T2DM. 
Therefore the main question addressed in this project is whether miR-29a is a regulator of 
STX1A. Additionally the impact of elevating the glucose level is assessed. An in vitro assay is 
performed, using a dual luciferase system in INS-1E cells of rats. 
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2 Methods 
2.1 Preparation of vectors 
2.1.1 DNA-oligos 
The following DNA-oligos were ordered from Eurofins MWG Operon: 
Stx1a Sense sequence: CTAGAGGTAC CTGGGGACCA GCTGGTCACA TGGTGCTGCT TTTGGCCGG 
Stx1a Antisense sequence: CCAAAAGCAG CACCATGTG ACCAGCTGGT CCCCAGGTAC CT 
Scr Sense sequence: CTAGAGCTAG CTGGGGTCGA CCAGACTAGC TGGCTAGTCT TTTGGCCGG 
Scr Antisense sequence: CCAAAAGACT AGCCAGCTAG TCTGGTCGAC CCCAGCTAGC T 
Mut2 Sense sequence: CTAGACTCGA GTGGGGACCA GCTGGTCACA TGTTACTGCT TTTGGCCGG 
Mut2 Antisense sequence: CCAAAAGCAG TAACATGTGA CCAGCTGGTC CCCACTCGAG T 
Perf Sense sequence: CTAGAAAGCT TTGGGGTAAC CGATTTCAGA TGGTGCTACT TTTGGCCGG 
Perf Antisense sequence: CCAAAAGTAG CACCATCTGA AATCGGTTAC CCCAAAGCTT T 
DNA is stored at +4°C or -18°C. 
2.1.2 Digestion of pGL4.13 
2.8 µg pGL4.13, 5 µl 10x NE buffer 4 and 1 µl 100x BSA were mixed and added 17 µl DNAse 
free water to a total volume of 50 µl. Digestion was done by adding 20 units XbaI and 4 units 
FseI and incubating 60 minutes at 37°C. The sample was then heat inactivated for 20 minutes 
at 65°C and stored at -20°C until use. 
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2.1.3 Preparation of agarose gel 
A solution for a 1 % agarose gel in TBE buffer was poured into a gel cast. The gel was dried for 
30 minutes at RT and additional TBE buffer was poured over the gel to prevent it from drying 
out. The gel was then sealed in plastic and stored at 4°C. 
2.1.4 Gel electrophoresis for purification of digested pGL4.13 
The gel was loaded with 10 µl digested DNA + 5 µl loading buffer in each well. The gel ran at 
100 V for about 60 minutes. 
Loading buffer 
50 mM Tris HCL pH 8.0 
25 mM EDTA 
20 % Sucrose 
Added Bromphenol blue 
2.1.5 Purification of digested vector 
Purification was done with GenElute Gel Extraction Kit from Sigma-Aldrich, cat: NA1111, 
according to manufacturer’s protocol. Concentration of purified vectors was measured on a 
Nanodrop 1000. 
2.1.6 Annealing of DNA-oligos 
Oligos were suspended in DNAse free water to a concentration of 100 µM. 1 µl of each 
matching sense and anti-sense oligos were mixed together in four safelock tubes. 48 µl 
annealing buffer was added to each tube. The samples were boiled for 2 minutes and cooled 
down ON. Samples are saved at -20 ˚C until use.  
Annealing buffer 
Made by lab technician  
984.4 mg KAc 
714.9 mg HEPES-KOH pH 7.4 
42.9 mg MgAc tetrahydrate  
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These were added to a 100ml cylinder. Milli-Q H2O is added to a total volume of 70 ml. pH is 
corrected to 7.4 with KOH. Add milli-Q H2O up to a total volume of 100 ml. The solution is 
autoclaved. 
2.1.7 Phosphorylation of DNA oligos 
 Phosphorylation of oligos was accomplished with the T4 PNK kit from Fermentas #K0031, 
but with 1 µl 1 µM ATP solution added.  
2.1.8 Ligation of DNA oligos and pGL4.13 
The oligos were ligated into the vector with a ratio of 2 µl oligo/3 µl vector. The negative 
control contained pGL4.13 and water. Ligation procedure followed Fermentas’ Rapid Ligase 
kit #K1421 protocol. 
2.1.9 Preparation of LB media and E. coli 
The E. coli culture was obtained from the DH5-α cell line. Bacteria have been grown in LB 
solution made with LB Broth EZMix from Sigma, cat: L-7658, according to manufacturer’s 
protocol. Agar plates were made with LB Agar tablets from Sigma, cat: L-7025, according to 
manufacturer’s protocol. 
2.1.10 Transformation 
Transformation was based loosely on the protocol by Froger & Hall (2007). 
A competent DH5-α E. coli culture was taken from a -80°C freezer and thawed in an ice bath. 
10 µl of vector was mixed with 100 µl competent E. coli cells in Falcon tubes. Only 1 µl of 
undigested pGL4.13 was used for the negative control because more colonies were expected 
when using this vector. Tubes were incubated for 30 minutes on ice and then exposed to heat 
shock for 45 seconds at 42°C. 250 µl preheated LB media was added and tubes were 
incubated for 30 minutes at 37°C while shaking. 350 µl was plated on LB-AMP plates. Only 
100 µl containing uncut vector was plated, again to avoid too many colonies. Plates were dried 
for 20 minutes at RT and incubated ON at 37°C turned upside down. 
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After transformation, E. coli cultures were collected and single colonies were both plated and 
suspended in LB media containing ampicillin. The new plates were incubated at 37°C 
overnight. Afterwards, the plates from which the colonies were picked, were sealed with 
parafilm and stored at 4°C turned upside down.  
2.1.11 Minipreps for restriction analysis 
Minipreps were done according to GenElute Plasmid Miniprep Kit from Sigma-Aldrich, cat: 
PLN 350. 
Obtained DNA concentrations were not measured for the restriction analysis. 
2.1.12 Restriction analysis 
Six minipreps from each transformation were digested, and each digestion was done 
according to Table 2, with DNAse free water added to a total volume of 20 µl. Digestions were 
incubated for 2 hours at 37°C, and heat inactivated for 20 minutes at 65°C. Digestions were 
stored on ice since KpnI cannot be heat inactivated. 
Plasmid 
Restriction 
enzyme 
NEBuffer nr. BSA volume 
2 µl Stx1a-
plasmid 
KnpI (10 units) 2 µl 10xNEbuffer 1 0.2 µl 100x BSA 
2 µl Scr-plasmid NheI (10 units) 2 µl 10xNEbuffer 2 0.2 µl 100x BSA 
2 µl Mut2-
plasmid 
XhoI (20 units) 2 µl 10xNEbuffer 4 0.2 µl 100x BSA 
2 µl Comp-
plasmid 
HindIII (20 units) 2 µl 10xNEbuffer 2 - 
Table 2: Overview of each digestion reaction 
Afterwards, 10 µl of each digestion was loaded with 10 µl loading buffer on a 1 % agarose gel. 
The gel ran at 120 V for 1.5 hours. 
The Mut2-construct was digested again, for a better result. All volumes were added as 
previous digestion, but digestion was incubated ON at 37°C and gel ran for 2.5 hours. 
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2.1.13 Midiprep 
Midipreps were made according to Qiafilter plasmid midi kit from Qiagen, cat: 12243. 
Precipitation was done by mixing 50 % midiprep volume with 1.25 times 96 % ethanol and 10 
% sodium acetate for each product. After precipitation, samples were measured on a 
spectrophotometer with 2 µl of sample in 98 µl M.Q. water. 
2.1.14 Sequencing 
200 ng of the vectors were sequenced according to Applied Biosystems Prism Bigdye 
Terminator v.1.1 Cycle Sequencing Kit. 
2.2 Growth of INS-1E 
Complete Media: 
RPMI 1640 w. glutamax, Invitrogen 61870-044 500ml 
Supplemented with: 
Pen/strep, Invitrogen 15140-114      5ml  
Mercaptoethanol, Invitrogen 31350-010  500μL 
FCS, heat inactivated   10% (500ml media, 50ml FCS 
Media for 5 mM and 20 mM glucose: 
RPMI 1640 w. L-glutamine, without glucose, Sigma 11879-020 500 ml 
Supplementet with: 
Pen/strep, Invitrogen 15140-114      5ml  
Mercaptoethanol, Invitrogen 31350-010  500μL 
FCS, heat inactivated   10% (500ml media, 50ml FCS 
1M glucose to a final solution of either 5 mM glucose or 20 mM glucose. 
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Trypsin-EDTA: Invitrogen 35400-027. Divided in 5 ml and stored at -20°C. When the Trypsin 
is defrosted, 45 ml PBS without calcium or magnesium is added. 
Pen/Strep: Invitrogen 151400-114. Divided in 5 ml and stored at -20°C. 
PBS without Ca or Mg: Invitrogen 14190-094. 
Trypsination: 
The rest of the cell growth was done by lab technicians. 
T75 flasks are washed twice with 10 ml PBS without Ca2+ and Mg2+ ions. 1.25 ml Trypsin-
EDTA is added and cells are incubated approx 3 min. 9 ml complete media is then added while 
spreading the cells by pipetting up and down with 10 ml automatic pipette. The cells are spun 
down in a 15 ml swing-bucket rotor for 5 min at 1000 rpm and are resuspended in complete 
media to remove inactivated trypsin. Cells are counted in hemocytometer and the cell number 
is given by: 
Counted cells in a 16-quadrant space * 10.000 = cells/ml. 
Plate INS-1E cells as follows: 
 T25: 1*106 cells in a volume of 5-6ml 
 T75: 3 *106 cells in a volume of 17-20ml 
 T150: 6*106 cells in a volume of 35-40ml 
The cells are split 1 time each week (Monday) and the media is changed every second or third 
day (Monday, Wednesday, Friday). INS-1E is used for experiments in passages below 105 – a 
new ampule of cells is thawed at passage 103. 
Cells were set up for transfection with 200.000 cells/well in a 24 well setting. 
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2.3 Dual luciferase assay 
All transfections were done in INS-1E cells and with Lipofectamine 2000 according to the 
manufacturer’s protocol. 
2.3.1 RNA/LNA oligos 
The following oligos were ordered: 
miR-29a mimic: rno-miR-29a meridian mimic. Dharmacon, cat: c-320321-05-005 
miR-29a knockdown LNA: rno-miR-29a mercury LNA knockdown probe. Exiqon, cat: 
141278-00 
scrambled knockdown LNA: Scramble-miR control mercury knockdown probe. Exiqon, cat: 
199002-00 
RNA and LNA Oligos are stored at -80°C 
2.3.2 Transfection with 11 mM glucose 
For all transfections, old media from a 24-well plate was aspirated, and 400 µl fresh Complete 
media added to each well. DNA mastermixes were made. LF2000-Optimem mastermix was 
incubated for exactly 5 minutes at RT and added to the DNA mastermixes and incubated for 
20 minutes at RT. 
20 wells were transfected with a solution containing 1 µg vector, 5 ng pRL, 1 µl LF2000 and 
optimem added to 100 µl. Plates were incubated ON at 37°C, 5 % CO2 and 100 % relative 
humidity. 
2.3.3 Transfection with 5 mM and 20 mM glucose 
Cells were washed twice with RPMI 1640 w. L-glutamine without glucose to remove any 
remaining glucose. Six DNA mastermixes were made. LF2000-Optimem mastermix was 
incubated for exactly 5 minutes at RT and added to the DNA mastermixes and incubated for 
20 minutes at RT. 
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30 wells were transfected with 1 µg DNA, 5 ng pRL, 1µl LF2000 and Optimem added to a total 
volume of 100 µl and incubated ON at 37°C, 5 % CO2 and 100 % relative humidity. 
2.3.4 Transfection with RNA oligos and DNA at 11 mM glucose 
45 wells were transfected with 1 µg DNA, 50 pmol RNA, 5 ng pRL and 1 µl LF2000 in Optimem 
up to 100 µl and incubated ON at 37°C, 5 % CO2 and 100 % relative humidity. 
2.3.5 Measurements of luciferase activity  
The luciferase assay was performed according to the Promega Dual-Luciferase® Reporter 
Assay System. According to the protocol 20 µl of lysate is ideal for the measurements, but 5 µl 
of lysate was used for the 11 mM transfection and 3 µl for the 5 mM and 20 mM transfection 
to obtain measurements within the range of the spectrophotometer used. Other steps of the 
assay were applied as the protocol states. 
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3 Results 
The dual luciferase assay requires extensive laboratory work. The following will describe the 
performed steps with short explanations. 
 4 DNA-oligos were designed to serve as either the miR-29a target site from Stx1a, 
negative controls or a positive control 
 DNA-oligos were cloned into the pGL4.13 vector to obtain the needed constructs 
• The single stranded DNA-oligos were annealed and phosphorylated to permit 
ligation 
• pGL4.13 was digested and purified to prepare it for ligation 
• pGL4.13 and DNA-oligos were ligated 
 Constructs were multiplied for later use in transfections 
• Constructs were transformed into E. coli 
• A small amount of constructs were purified with mini-preps 
• Restriction analysis was performed to ensure that the cloning process went as 
expected 
• Constructs were purified again with midi-preps to obtain DNA for transfections 
 Sequence analysis was performed to ensure that the constructs contained the correct 
oligos 
 INS-1E cells were cultured and prepared for transfections 
 INS-1E were transfected with constructs in five different setups 
 Luciferase activity was measured after incubation of transfected cells 
The dual luciferase assay is designed to test the hypothesis that there is an interaction 
between the predicted target site and miR-29a. This would be evident if a significant 
difference between the negative control and the positive control is found. An interaction 
would indicate that Stx1a contains a genuine target site for miR-29a. Potentially this 
experimental setup also makes it possible to evaluate the efficiency of the target site, as 
the result may be close to or far from the maximal possible regulation shown by the 
positive control. 
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3.1 Preparation of constructs 
3.1.1 Design and Cloning of DNA-oligos 
The plasmid pGL4.13 is used as a cloning vector. Four different inserts were designed and 
cloned into the plasmid. The following four DNA-oligos were designed: Syntaxin 1A (Stx1a), 
Scrambled (Scr), Point mutated (Mut2) and Perfect (Perf). The Stx1a-oligo contains the miR-
29a target site from the 3’ UTR of rat Stx1a mRNA. The Scr-oligo is the same length as the 
Stx1a-oligo and has no target sites for either miR-29a or any other miRNAs expressed in rats, 
mice or humans, thereby acting as a negative control. The Mut2-oligo is similar to the Stx1a-
oligo, but has two point mutations in the miR-29a seed sequence, and thus also acts as a 
negative control. The Perf-oligo contains a sequence which is perfectly complementary to 
miR-29a, acting as a positive control.  
Several considerations were made in the design process. First, it is important that the binding 
affinity of miR-29a for the oligo, which only contains a small part of the entire 3’ UTR, is 
closely matched to that of the actual miR-29a target site of Stx1a. For this purpose, the DNA 
oligos does not only contain the target site, but also 5 nt of the original sequence around it. 
The reason why only 10 extra nt were added, was to keep the oligo size to a minimum to 
ensure an effective cloning. Furthermore it is important to be able to investigate whether the 
cloning process was successful. This was carried out by designing each oligo with specific and 
unique restriction sites, see section  3.1.2. To be able to eliminate other miRNAs affecting the 
results, all DNA-oligos were screened for other predicted target sites, using the TargetScan 
and MiRBase algorithms. This search identified several potential target sites for miRNAs, but 
none that are expressed in rats, mice or humans.  
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Stx1a: 
         KpnI 
  CTAGAGGTAC CTGGGGACCA GCTGGTCACA TGGTGCTGCT TTTGGCCGG 
 Seed seq. 
Scr: 
         NheI 
  CTAGAGCTAG CTGGGGTCGA CCAGACTAGC TGGCTAGTCT TTTGGCCGG 
 
Mut 2: 
         XhoI 
  CTAGACTCGA GTGGGGACCA GCTGGTCACA TGTTACTGCT TTTGGCCGG 
  Seed seq. 
Perf: 
         HindIII 
  CTAGAAAGCT TTGGGGTAAC CGATTTCAGA TGGTGCTACT TTTGGCCGG 
 Seed seq. 
Figure 2: Sense sequence of DNA oligos. The gray marked region is the miR-29a target site on the oligos and 
seed sequence is underlined. The specific restriction enzyme cutting the inserting site is stated above the 
sequence. 
Figure 2 contains all the sequences of the designed DNA-oligos used as inserts. Only the sense 
sequence with restriction site overhangs are shown, but antisense oligos were designed as 
well. These sequences were cloned into pGL4.13. The following restriction analysis and 
selection for plasmids with antibiotic resistance determined if they, in fact, were inserted in 
the vector. 
As mentioned, the plasmid used as vector is pGL4.13, see plasmid card in Appendix  8.3. It 
contains AmpR, an ampicillin resistance gene. During the cloning process, the AmpR gene is 
used to select plasmids with antibiotic resistance also called positive selection. This was 
carried out by growing the cloned plasmids on media containing ampicillin, only allowing cells 
with annealed plasmids, which are able to express the AmpR gene, to survive. The results of 
the selection can be seen on Figure 3. 
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Figure 3: All plates are LB-AMP plates, with E. coli growing ON at 37°C. A: 350 µl digested pGL4.13. Number of 
colonies is estimated to 264. B: 350µl pGL4.13 from the transformation with the Perf-oligo. C: 100 µl 
undigested pGL4.13. The number of colonies on both the right and middle plates far exceeds number of 
colonies on negative control. 
As seen on Figure 3, the digested vector has a considerably lower number of colonies than 
both the plate with the transformed E. coli and the undigested pGL4.13. Each colony 
represents E. coli cells which expresses a plasmid with the AmpR gene. The digested vector 
serves as a negative control where colonies show the effectiveness of the digestion procedure. 
Because relatively few E. coli cells survived, it can be assumed that the digestion was very 
effective. The undigested vector serves as a positive control as no digestion has been made, 
allowing for all transformed E. coli to express the resistance gene. Because the positive and 
negative controls were as expected, the plate containing colonies with constructs should 
primarily contain E. coli with plasmids that have been cloned, re-ligated and transformed. All 
results from the four transformations were similar, and were used for the restriction analysis. 
3.1.2 Restriction analysis 
After positive selection of E. coli colonies, a restriction analysis was performed to confirm that 
the insert with the target sites were present in the constructs. The restriction enzymes used to 
cut the different oligos were Kpnl, Nhel, Xhol and HindIII. Each oligo was constructed to 
contain one unique restriction site for one of the enzymes. The introduced sites are also 
present in the plasmid pGL4.13, which makes it possible to compare both fragment sizes and 
numbers. Because each oligo has one specific site, it is also possible to distinguish between 
them among each other if needed. 
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Table 3 shows the result of calculations of expected fragment sizes based on the restriction 
sites. pGL4.13 is 4641 bp, and the inserts are 49 bp. Cutting the pGL4.13 with XbaI and FseI 
removes a fragment of 19 bp. This makes the expected size of the cloned plasmids 4671 bp 
(4641 bp+49 bp – 19 bp). Calculations of individual fragments are based on the location of the 
restriction site in both the vector and inserts. All inserts have their 5’ end located at the XbaI 
site (2157bp) in pGL4.13. From the plasmid card in Appendix  8.3, all restriction sites and thus 
fragment sizes can be calculated. 
Clones Enzyme and restriction sites Fragment size (bp) 
Stx1a-plasmid KpnI at 19, 103 and (2157+10)= 2167 84, 2064 and 2523 
Scr-plasmid NheI at 28 and (2157+6)= 2163 2135 and 2536 
Mut2-plasmid XhoI at 34 and (2157+6)= 2163 2129 and 2542 
Comp-plasmid HindIII at 465 and (2157 + 6)= 2163 1698 and 2973 
Table 3: The restriction sites of the inserted oligos is found by calculating the distance between the 
restriction sites. In total the pGL4.13 has 4671bp after insert.  
After digestion the constructs were run on an agarose gel. All fragment sizes from Table 3, 
except the 84 bp fragment, is expected to be in the range of the 1 kb plus DNA ladder used, 
and should be distinguishable from each other. 
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Figure 4: LEFT: 1 kb plus ladder from Invitrogen. Right: Agarose gel from digestion and electrophoresis of the 
four clones. The wells to the left contain: 5µl 1kb plus DNA ladder from Invitrogen, followed by 6 wells 
containing 10 µl digested mix + 10 µl loading buffer. All digestions were incubated for 120 minutes. The gel has 
been run at 120 V for 90 minutes. A depicts the Stx1a-construct digested with KpnI, B depicts the Scr-construct 
digested with NheI, C depicts the Mut2-construct digested with XhoI and D depicts the Perf-construct digested 
with HindIII. There are visible fragments at the expected size range from all digestions, but the Mut2-construct 
and Perf- construct also contain some unexpected fragments in some preparations.  
Figure 4 shows the results from the gel electrophoresis of the digested clones. Each clone was 
prepared and run in six separate preparations. The sizes of the bands from all the 
preparations are generally a little larger than the calculated ones. This discrepancy is 
applicable for all digestions which suggest a general problem, and not necessarily wrong 
constructs.  Because it is only a small deviation from expected values and because sizes are 
correct relative to each other, this inaccuracy is neglected.  
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Both the Stx1a-construct (A) and Scr-construct (B) digestions produced two distinct bands in 
all samples. The upper fragment is ca. 3 kbp and the lower one is ca. 2.5 kbp. For the Perf-
construct (D), all the six wells have two visible bands at about 2 kbp and 3.5 kbp, which are 
expected when accounting for the size discrepancy. The digest of the Perf-construct number 2, 
3 and 5 has an additional two bands visible at about 5 kbp and one that has not migrated. It is 
assumed that the 5 kbp band is the undigested or semi-digested plasmid, while the non-
migrated one consists of super coiled DNA. 
The Mut2-construct digest shows two rather weak but expected bands, similar to the first two 
digestions at 2.5 kbp and 3 kbp. A much stronger third band is visible at about 5 kbp, which 
could be an undigested or semi-digested plasmid. Because different restriction enzymes were 
used for each plasmid, an explanation for the difference in amount of digested plasmid could 
be that XhoI needs a longer incubation time to cut the plasmid than the others. Therefore 
another digestion was made with longer incubation time, see Figure 5. 
 
Figure 5: Gel of restriction enzyme digest of Mut2-construct. The digestion was made with XhoI and incubated 
ON. The gel was run at 120 V for 150 minutes. Two clear bands are visible in all six digestions, with sizes at 
about 2.5 kbp and 3 kbp. The ladder used is 1 kb Plus DNA from Invitrogen – see Figure 4. 
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Figure 5 shows the gel electrophoresis of the second digestion and electrophoresis of Mut2-
construct, using the restriction enzyme XhoI. Only the two expected bands are visible after 
this second digestion, which gives validity to the hypothesis about a too short incubation 
period for XhoI in the first digestion. 
In summary, at least one of the digestions of each construct appears to be correct in size 
relatively to each other. Assuming the size discrepancy can be neglected, and given that the 
correct number of fragments is visible, it can be concluded that all the wanted clones were 
successfully constructed. 
3.1.3 Sequence analysis 
Sequence analysis of the constructs from the transformation is carried out by comparing 
expected (synthesized) oligo sequences with the ones sequenced. It is a precise method to 
verify both the sequence of the ordered oligos and that they are inserted as expected. In the 
oligos most nucleotides have a specific role to play; even a single inconsistency in the 
sequence could have adverse effects on the results of the transfection experiment. If for 
instance one of the nt making up the seed sequence of miR-29a is changed, binding affinity 
could be severely lowered. It is also possible to introduce new miRNA targets by changing 
single nucleotides. The sequences are compared to expected results in Chromas Lite, for both 
forward and reverse primers. 
The alignment is done by searching for the expected sequence in the sequenced data. The 
constructs are verified if there is a complete match between both the sequences obtained by 
using the forward and reverse primers and if the data output seems valid.  
The chromatograms of the sequencing are depicted in the figures at the end of this section. 
Capital letters in the sequences stated above the figures describe that it is the target site part 
of the oligo with 5 nt on each side, where lower case letters describe restriction enzyme sites 
and overhang. 
All sequenced data seems to correlate with the expected result. Some of the sequences seems 
to be interpreted a bit erroneously by the software and needs to be corrected. 
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The data in Figure 6,Figure 8, Figure 9 and Figure 11 shows no inconsistencies between the 
expected and the sequenced data. All nucleotides are aligned and are easily interpreted by 
both the software and manual analysis. The data quality leads to a very low risk of 
misinterpretation. 
In the sequence of Figure 7, nt 135 is stated as a N, an unknown nucleotide. This 
interpretation from Chromas lite can be easily dismissed by looking at the data. It seems clear 
that no fluorescence of notable magnitude can be placed between nt 134 and 136. When the 
false positive nt 135 is removed, the sequence matches that of the expected one, as with the 
forward primer.  
Figure 10 shows three specifically interesting nucleotides, namely the N’s at 112 and 116 and 
the unknown at 114. By examining the figure it is clear that the two N’s can be explained by 
software misinterpretations. There is no fluorescence peak at either nt 112 and 116, and the 
N’s can thus be removed. The nt at position 114 was not identified by the software, but can be 
recognized as a fairly strong cytosine signal by a closer examination. When the sequenced 
data is corrected for these inconsistencies, it correlates to a perfect match to the expected 
oligo sequence. 
By comparing the sequenced oligo in Figure 12 with the expected results there is a 
discrepancy in the number of nucleotides. The adenine expected to be at position 91 is not 
counted by the software. When examining the figure, it seems plausible that the rather 
significant adenine peak at that position is overlooked by the software because it is 
overshadowed by the guanine peak. When it is counted the expected and sequenced data 
matched perfectly. 
Figure 13 shows three misinterpretations made by the software. Nt 96, 112 and 126 is stated 
as unknown, but as with the other sequences, clear peaks which are not counted is evident at 
each location. Nt 96 and 126 has clear guanine peaks and nt 112 is a thymine peak. 
After analysis of the inconsistencies of the data it is recognized that all sequences match the 
expected ones. It is therefore reliable to conclude that the four oligos, in fact, has been cloned 
into the pGL4.13 vector as was hypothesized from analysis of the restriction enzyme digest. 
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Sense sequence of Stx1a-construct (49 nt) 
Expected/Sequenced:  ctagaggtac cTGGGGACCA GCTGGTCACA TGGTGCTGCT TTTggccgg  
 
Figure 6: Data output of sequenced Stx1a-construct using the forward primer, interpreted by using Chromas 
Lite. The constructs sequence spans over nt 115-163, in total 49 nt. Sequenced data shows:  CTAGAGGTAC 
CTGGGGACCA GCTGGTCACA TGGTGCTGCT TTTGGCCGG 
Antisense sequence of Stx1a-construct (41 nt) 
Expected/Sequenced: ccAAAAGCAG CACCATGTGA CCAGCTGGTC CCCAggtacc t 
 
Figure 7: Data output of sequenced Stx1a-construct using the reverse primer, interpreted by using Chromas 
Lite. The constructs sequence spans over nt 116-157, in total 42 nt. Sequenced data shows:  CCAAAAGCAG 
CACCATGTGN ACCAGCTGGT CCCCAGGTAC CT where the marked nt is specifically interesting. 
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Sense sequence of scrambled-construct (49 nt) 
Expected/Sequenced: ctagaGCTAG CTGGGGTCGA CCAGACTAGC tggctagtCT TTTggccgg 
 
Figure 8: Data output of sequenced Scr-construct using the forward primer, interpreted by using Chromas Lite. 
The constructs sequence spans over nt 121-169, in total 49 nt. Sequenced data shows:  CTAGAGCTAG 
CTGGGGTCGA CCAGACTAGC TGGCTAGTCT TTTGGCCGG 
Antisense sequence of Scr-construct (41 nt) 
Expected/Sequenced: ccAAAAGact agccaGCTAG TCTGGTCGAC CCCAGCTAGC t  
 
Figure 9: Data output of sequenced scr-construct using the reverse primer, interpreted by using Chromas Lite. 
The constructs sequence spans over nt 115-155, in total 41 nt. Sequenced data shows: CCAAAAGACT 
AGCCAGCTAG TCTGGTCGAC CCCAGCTAGC T 
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Sense of Mut2-construct (49 nt) 
Expected/Sequenced: ctagactcga gTGGGGACCA GCTGGTCACA TGtTaCTGCT TTTggccgg  
 
Figure 10: Data output of sequenced Mut2-construct using the forward primer, interpreted by using Chromas 
Lite. The constructs sequence spans over nt 108-157, in total 51 nt. Sequenced data shows: CTAGNACTNC 
GAGTGGGGAC CAGCTGGTCA CATGTTACTG CTTTTGGCCG G where the marked nt are specifically interesting. 
Antisense of Mut2-construct (41 nt) 
Expected/Sequenced: ccAAAAGCAG tAaCATGTGA CCAGCTGGTC CCCActcgag t  
 
Figure 11: Data output of sequenced Mut2-construct using the reverse primer, interpreted by using Chromas 
Lite. The constructs sequence spans over nt 95-135 in total 41 nt. Sequenced data shows: CCAAAAGCAG 
TAACATGTGA CCAGCTGGTC CCCACTCGAG T 
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Sense of Perf-construct (49 nt) 
Expected/Sequenced: ctagaaagct tTGGGGtaac cgatttcaga tggtgctaCT TTTggccgg 
 
Figure 12: Data output of sequenced Perf-construct using the forward primer, interpreted by using Chromas 
Lite. The constructs sequence spans over nt 85-132, in total 48 nt. Sequenced data shows: CTAGAAGCT 
TTGGGGTAAC CGATTTCAGA TGGTGCTACT TTTGGCCGG where the marked nt are specifically interesting. 
Antisense of Perf-construct (41 nt) 
Expected/Sequenced: ccAAAAGtag caccatctga aatcggttaC CCCAaagctt t 
 
Figure 13: Data output of sequenced Perf-construct using the reverse primer, interpreted by using Chromas 
Lite. The constructs sequence spans over nt 90-130, in total 41 nt. Sequenced data shows: CCAAAANTAG 
CACCATCTGA AANCGGTTAC CCCAAANCTT T where the marked nt are specifically interesting. 
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3.2 Dual luciferase assay 
The primary objective of the dual luciferase assay is to assess, whether miR-29a interacts with 
the predicted target site from Stx1a. Moreover it can indicate whether miR-29a is glucose 
induced. 
The target site and negative as well as positive controls were cloned into pGL4.13 containing 
luc2, the gene coding for Firefly luciferase (FF). This construct serves as a model, where 
expression of FF is a measurable indication of STX1A expression. A dual luciferase assay is 
used to measure protein expression. In this method FF activity is related to the activity of 
Renilla luciferase (RL). The expression of the RL enzyme is thought to be unaffected by the 
transfected constructs and hence constitute a reference for the basic level of luciferase 
activity. The advantage of looking at relative and not at total FF activity is that the amount of 
cells transfected and measured do not affect the results. Alternations in the ratios between FF 
and RL activity reflect the effect the endogenous miR-29a exerts on the different constructs. 
The constructs are the basis for examining the predicted binding of miR-29a to the target site 
on Stx1a. If miR-29a binds to the target site in the constructs, protein expression of the FF 
enzyme will be suppressed which will lower the FF/RL ratio. The constructs containing the 
genes for FF and RL both rely on the SV40 early enhancer, a constitutive promoter. Thus no 
difference in expressions of the two luciferases due to regulation of the promoter is expected. 
It is expected that the lowest FF/RL ratio is obtained from transfections with the Perf-
construct, since the inserted site in the 3’UTR of luc2 is perfectly complementary to miR-29a. 
With a perfect binding, it is anticipated that miR-29a exerts the highest suppression of the 
translation of FF mRNA, acting as a positive control. Transfections with pGL4.13, Scr-
construct and Mut2-constructs are expected to have similar and high FF/RL ratios, having no 
target sites for miR-29a, acting as negative controls. The FF/RL ratio of transfections with the 
Stx1a-construct is expected to lie within the range from the positive to the negative control.  
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3.2.1 FF is slightly down-regulated due to having the miR-29a target site of Stx1a in the 3‘UTR 
Three assays were performed to investigate, whether miR-29a binds to the predicted target 
site in Stx1a. The transfections were carried out with different amounts of glucose, 5 mM and 
20 mM in triplicates for 48 hours and 11 mM in quadruplicates for 24 hours. Each assay was 
performed with 5 different plasmids in INS-1E β-cells. The results of the 5 mM and 20 mM 
assays might be influenced by long-term effects of the glucose levels, which make a 
comparison with the results of the 11 mM assay unreliable. 
In order to verify a down-regulation of Stx1a by miR-29a, it is necessary to have negative 
controls that are not significantly affected by the level of miR-29a, and a positive control that 
shows a significant regulation by miR-29a levels. 
Figure 14 A shows the average of the FF/RL ratio for each of the transfections in 5 mM and 20 
mM glucose after 48 hours incubation. Statistics are applied to determine whether there are 
significant differences between the ratio of Stx1a and the controls. However it is obvious that 
Perf and pGL4.13 are much lower than Stx1a and the negative controls and therefore no 
statistical analysis is applied. 
For the 5 mM assay Stx1a is significantly lower than Scr (P-value=0.03) and Mut2 (P-
value=0.02). Yet, for the 20 mM assay only Stx1a and Scr was significantly different (P-
value=0.04). There is no significant difference between Scr and Mut2 in either the 5 mM assay 
(P-value=0.15) and 20 mM (P-value=0.55), see Appendix  8.4 for details of statistics. In the 11 
mM assay the cells were only incubated for 24 hours. As depicted in Figure 14 B, there is no 
significant difference between Stx1a and Scr (P-value=0.36) 
 Figure 14: A: The figure depicts the ratio between the FireFly (FF) and Renilla (RL) luciferase. Each column 
represents one of the five transfections with pGL4.13 with inserts containing
(Stx1a) from the 3‘ UTR of Stx1a, the scrambled sequence (S
seed sequence (Mut2), the sequence perfectly complementary to 
(pGL4.13). The assays were performed with 5 mM and 20 mM glucose which they were exposed to for 48 hou
Standard deviation is shown as error bars. Columns marked with (*) are significantly different from 
mM glucose. The column marked with (¤) is significantly different from 
depicted in the figure is similar to that of figure A, except that cells were incubated for 24 hours with 11 mM 
glucose. The column marked with (^) is significantly different from 
found between Scr and Mut2, but this is not indicated on the figure.
significantly lower than Stx1a on both figures.
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The theory suggests that the difference between the controls and Stx1a can be used to show 
the regulation pattern by miR-29a, as long as the controls act as expected. This means that the 
controls have to be analyzed before any convincing conclusions can be made from the data. 
Both in the 5 mM and 20 mM assay the negative controls Scr and Mut2 are not significantly 
different from each other, which confirms the expectation that they equally regulated in the 
cells. It was also expected that the third negative control pGL4.13 had a similar activity to the 
two other negative controls, but it is considerably lower in all the assays. The pGL4.13 vector 
used for the transfection was not freshly harvested from E. coli as all the other plasmids, but it 
was from an older preparation. Hence the DNA quality and concentration might have been 
lower than anticipated resulting in a less effective expression of FF from the vector. Though 
Stx1a has higher results compared to pGL4.13, it cannot be ruled out that the predicted target 
site of Stx1a is targeted by miR-29a. The positive control Perf is also different from both 
negative controls in all three assays, which was necessary. It is problematic to relate the 
negative controls Mut2 and Scr in the 11 mM assay to the Stx1a regulation because they are 
significantly different from each other. It is therefore not certain which of the controls, if any, 
that can be used as reference. It is also important to note that the exposure time of the 11 mM 
assay was different from the other two assays. Even though the positive control and the Mut2 
are significantly different from Stx1a, it would not be appropriate to include the 11 mM assay 
to argue for or against miR-29a regulation.  
When comparing the regulation patterns within the assays, the 5 mM assay implies a down-
regulation of Stx1a by miR-29a. Yet the 20 mM assay is ambiguous. Regarding the standard 
variation and small sample sizes, these results might be random irregularities caused by the 
small amount of data investigated or an imprecision in performing the assay. A way to 
minimize the irregularities and to obtain less ambiguous results would be to replicate the 
assays and carry out transfection in quadruplicates. 
The obtained data might not be sufficient to describe the function of miR-29a as a regulator. 
With the current setup, the data relies only on the amount of endogenous miR-29a. It would 
have been favorable to have transfections where the amount of miR-29a is both up-regulated 
and knocked-down. Note that this transfection was performed but failed, see section  3.2.3. In 
summary, it is difficult to distinguish coincidences from actual interactions in the cells. With 
the available data, no strong indication was found for the function of miR-29a as a regulator of 
 Stx1a in INS-1E cells. However, all the 
some cases even significantly. This suggests a slight interaction between 
3.2.2 Varying glucose levels have no impact on miR
There is a general tendency in the results that high glucose level of the media ha
effect on the FF/RL ratio. To investigate
transfections were done at two 
incubated for 24 hours is not compared with the two ass
possible long-term effects of glucose exposure. 
with varying glucose levels might indirectly indicate the glucose induced up
miR-29a. The reason for this 
compared to the 5 mM assay 
control. This would change the ratios between the positive control and the negative controls. 
Potentially it might even indicate that miR
response to high glucose level
ratios compared to the negative controls.
Figure 15: Ratio between the results of the 5 mM
with black bars. If the high glucose level up
and Stx1a would be higher than the ratios of the neg
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-29a is a mediator of STX1A down
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-regulates miR-29a expression, it is expected that the ratios of
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Figure 15 shows the ratio between the results from two assays with varying glucose 
concentrations (5 mM/20 mM). Perf and Stx1a are expected to have higher ratios than the 
negative controls, as the high glucose levels might up-regulate miR-29a expression and hence 
down-regulate FF expression and lower FF/RL ratios in these samples. The 5 mM/20 mM 
ratios show that Stx1a and Scr undergo the largest change in FF/RL ratio, followed by Mut2, 
Perf and pGL4.13. Considering the large standard deviations, there is no basis for concluding 
that the ratios differ from each other.  
There is no trend in the results indicating an up-regulation of miR-29a due to an increase in 
glucose concentration. According to the data, both FF and RL activity have been significantly 
down-regulated in the 20 mM glucose assay (data not shown), though the FF activity is 
considerably more down-regulated than RL by an unknown mechanism. A suggested 
explanation for these results is that a high glucose level specifically exerts an effect on the FF 
enzyme and/or expression. Since both the FF and RL plasmids used have an SV40 promoter 
the transcription of both should be regulated similarly.  
3.2.3 Failed dual-luciferase assay with cotransfection of RNA/LNA-oligos  
A dual luciferase assay was performed where RNA- and LNA-oligos were cotransfected along 
with the plasmids containing the genes for FF and RL.  
While relying on endogenous miR-29a in INS-1E cells in the varying glucose transfections, this 
setup uses RNA and LNA oligos to control the miR-29a amount in the cells. Three different 
oligos were cotransfected: miR-29a mimic, miR-29a knockdown LNA, and a scrambled 
knockdown LNA. The miR-29a mimic is an RNA molecule identical to miR-29a and is 
supposed to increase the regulation normally exerted by the endogenous miR-29a on Perf and 
Stx1a.  The miR-29a knockdown LNA is an LNA molecule complementary to miR-29a and is 
expected to bind irreversibly to the endogenous miR-29a. This knock-down serves as a 
negative control, theoretically equalizing the FF/RL ratios of all the transfections. The 
scrambled knockdown LNA molecule is not complementary to any miRNA and is expected not 
to affect FF activity. It is a negative control, which might tell something about the effect of 
overloading the cells with small LNA molecules. 
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Luciferase activities measured from the cotransfections with RNA- and LNA-oligos were all 
close to the measurements of water, making the data unusable. The assay was repeated in a 
smaller setup with the same results. In the larger first setup, contaminated optimem is a 
probable candidate for the failure. The media used or the act of changing the media might 
have killed the cells in the smaller transfection. The reason this is suggested is that cells where 
no media change occurred survived, while untransfected cells that had the media changed 
died. 
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4 Discussion 
The initial hypothesis was that miR-29a is a mediator of STX1A down-regulation due to 
hyperglycemia. The data shows a slight down-regulation of FF, when the target site from 
Stx1a is cloned into the 3’UTR of its gene. No major differences were found between the ratios 
of the relative luciferase activities of 5 mM and 20 mM glucose transfections. To interpret 
these results several considerations has to be taken into account. 
The most obvious drawbacks are the small amount of data and the failure of the RNA/LNA 
transfections. The experiments need to be replicated to obtain more representative data. 
Additionally the statistical tests would be far more reliable with more data. The failed 
RNA/LNA transfections would probably have contributed to confirm or disconfirm the 
hypothesis. In these transfections the level of miR-29a in the cells would have been controlled. 
Varying the level of miR-29a would ensure that the results would reflect the change in miR-
29a levels. In the setup without miR-29a variation other unknown variables might have 
caused the differences in luciferase activity. However, the transfections without RNA/LNA 
have the advantage of better mimicking physiological conditions.  
A critical point of the experiment is that the constructs have the expected functions. Especially 
the two negative controls offer many possibilities with respect to the design. To ensure that 
they function as anticipated the negative controls should be verified for this purpose in other 
experiments. However, the data does not give rise to question the used constructs.  
These weaknesses make it uncertain to conclude on the data and more experiments could 
indicate either way whether miR-29a targets Stx1a. 
The secondary objective of the experiment was to show that miR-29a is upregulated due to 
high glucose concentration. STX1A was shown down-regulated because of high glucose levels 
in β-cells after 72 h (Dubois et al., 2007). This could be caused by any number of factors, but if 
miR-29a is the mediator of this effect of glucose, one would expect miR-29a to be up-regulated 
no later than 72 h after increasing glucose concentration. However, there might be a 
considerable delay between up-regulation of miR-29a and its possible effect on STX1A levels. 
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What was shown most clearly in the data is the greatly lowered FF and RL activity at 20 mM 
glucose compared to 5 mM glucose. Furthermore the FF activity is down-regulated relatively 
more than RL. No mechanism is suggested to explain this phenomenon, but it is proposed that 
the luciferase reporter gene is not appropriate for monitoring glucose induced effects. 
Another explanation for the results is that miR-29a is not glucose induced, but it is considered 
that the unpublished data showing a glucose induced up-regulation of miR-29a is more 
reliable than the data from this experiment. 
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5 Conclusion 
Unfortunately a satisfactory answer to the main questions raised in this project cannot be 
given. The effect of high glucose concentration on the regulation on miR-29a could not be 
elucidated. Furthermore the performed dual luciferase assay seems to be an inadequate 
reporter system, when examining the effect of high glucose levels. It cannot be clarified 
whether Stx1a from rats contains a genuine target site for miR-29a and consequently might 
play a role in T2DM. However, the indicated slight regulation of Stx1a by miR-29a could be a 
motivation for further research. 
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6 Considerations for further research 
The possible connection to T2DM and the indication of a slight interaction between miR-29a 
and Stx1a could motivate to further examine the matter. To confirm the tendency found in the 
transfections without cotransfected oligos, it is necessary to reproduce the results. 
Furthermore an assay corresponding to our failed transfections, in which the RNA/LNA-oligos 
miR-29a mimic, scrambled miR-29a mimic and miR-29a complementary LNA are 
cotransfected with the constructs, could support these results. 
Additionally or alternatively, small supplements to the assay or other experimental setups 
could help elucidate the nature of the predicted target site. For instance one could try to clone 
the predicted target site into the vector several times to enhance the sensitivity of the system 
and ensure that at least one of the inserts is structurally accessible to miR-29a. An alternative 
approach is measuring the protein level directly instead of using a reporter gene system. A 
western blot could shed light on the cellular levels of Stx1a in response to different levels of 
miR-29a. MiRNA levels could be monitored by northern blots. It should be noticed that it is 
possible to perform both dual luciferase assays and a western blot in one setup, as only a 
small part of the cell lysate is used to for the luciferase measurements. The remaining lysate 
could be utilized in western blotting, if it contains a sufficient protein concentration.  
The miRNA research is a new field with a myriad of loose ends. Databases like TargetScan and 
MirBase still provides an incomplete picture of miRNAs; novel miRNAs are found regularly 
and many of the predicted target sites have yet to be confirmed or disconfirmed. There is a 
conflict between the notion of miRNAs being a fine-tuning mechanism and the idea of miRNAs 
being crucially important in protein expression regulation. This contributes to the difficulty of 
establishing a precise picture of the role of miRNAs. Therefore it is even more important to 
obtain unambiguous results and avoid drawing rushed conclusions. 
The idea of miRNAs acting cooperatively to enhance their individually slight regulation is a 
notion worth investigating further. MiRNAs might either work cooperatively by binding to the 
mRNA of the same protein or by binding to mRNAs of different proteins in one pathway. It 
might be interesting to examine other miRNAs having predicted target sites in the 3´UTR of 
Stx1a. Since miR-29a and miR-29b1 are located in close proximity on chromosome 4, it 
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suggests the transcription of these might be coupled (He et al., 2007) and this could be 
investigated further. They might target the same mRNAs, because of their similarity. Other 
proteins are involved in the dysfunction of the insulin secretion pathway in T2DM, perhaps by 
interacting with miRNAs (Saisho et al., 2009). Other miRNAs are shown to have a role in 
insulin secretion, for instance miR-375 (Poy et al., 2004), and it could be investigated how 
they are regulated. Obvious candidates for regulating miRNAs in T2DM are glucotoxicity and 
lipotoxicity. It could be investigated which miRNAs are regulated by high glucose and/or fatty 
acid levels. 
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8 Appendix 
8.1 Pathophysiology of Type 2 Diabetes Mellitus 
8.1.1 Pathogenesis of Type 2 Diabetes Mellitus 
T2DM is a heterogeneous group of disorders, in which an elevated blood glucose level, 
hyperglycemia, is caused primarily by an impaired response to insulin and a deficiency in 
insulin secretion (reviewed in Das & Elbein, 2006). The metabolic irregularities that 
characterize patients with T2DM include obesity, increased glucose production from 
hepatocytes, insulin resistance and reduced insulin secretion (Weyer, Bogardus, Mott, & 
Pratley, 1999). Insulin resistance can be defined as a change in insulin responses; hepatic 
glucose production is less inhibited and activation of glucose uptake in muscles is decreased 
relative to the normal effect of insulin (reviewed in Stumvoll, Goldstein, & van Haeften, 2005). 
However the precise order and the importance of the etiological factors in the pathogenesis of 
T2DM is a matter of debate and there may be multiple pathways leading to the disease. 
Complicating factors in elucidating this issue is the heterogeneity of the disease and the toxic 
effect of high glucose concentrations in the blood, glucotoxicity, which makes it difficult to 
distinguish causes and consequences of hyperglycemia (reviewed in Das & Elbein, 2006). 
Substantial evidence stresses the importance of insulin resistance, a dysregulation of the 
adipocyte as a secretory organ and a dysfunction of both the liver and the pancreatic β-cells in 
early stages of the disease (reviewed in Lin & Sun, 2010). 
8.1.2 The Role of Insulin Secretion in Type 2 Diabetes Mellitus 
It is clear that impaired insulin secretion is a crucial player in T2DM, but whether it is only a 
consequence of insulin resistance or a true cause of T2DM in itself, has been discussed 
vigorously (reviewed in Ferrannini, 1998). 
Normally glucose levels are kept very constant, primarily through the interplay of insulin 
secretion and action, e.g. in individuals with reduced sensitivity for insulin the uptake of 
glucose is ensured by increased insulin secretion (reviewed in Stumvoll et al., 2005). In that 
example β-cells fail to compensate for insulin resistance and T2DM is beginning to develop. It 
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should be noted that the insulin concentration in the blood is approximately doubled in 
patients with T2DM (Stumvoll, Tataranni, Stefan, Vozarova, & Bogardus, 2003), but 
nevertheless the β-cells are said to be impaired. The β-cells are measured by their ability to 
produce sufficient amounts of insulin to maintain constant glucose levels.  
An argument for a prominent role of insulin resistance is that slightly elevated glucose levels 
due to insulin resistance might be a sufficient cause for β-cell failure (reviewed in Stumvoll et 
al., 2005). However, glucose homeostasis might also be unbalanced by impaired β-cell 
function without the presence of insulin resistance (van Haeften et al., 2002). Hence an 
impaired insulin secretion may precede insulin resistance in the development of T2DM. 
Consequently the preceding etiological factor in T2DM may either be impaired insulin 
secretion or insulin action; in both cases one is leading to a deterioration of the other before 
the onset of T2DM. 
It is found that there might be a common source for β-cell dysfunction and insulin resistance. 
The causes include genetic predisposition, adipokines and inflammation, hyperglycemia and 
excess free fatty acids (reviewed in Stumvoll et al., 2005). Adipokines primarily lower insulin 
sensitivity of muscles, the primary glucose consuming tissue, partially due to induction of an 
inflammatory state (reviewed in Das & Elbein, 2006). Adipokines are signaling proteins 
secreted from adipocytes in response to GLUT4 down-regulation, which is a commonly 
observed metabolic irregularity in obese individuals (Shepherd & Kahn, 1999). The other 
causes contain an explanation for the progressive nature of the disease and also suggest 
possible mechanisms for how insulin resistance might cause β-cell dysfunction and vice versa. 
The effect of insulin resistance on β-cell function through an increased blood glucose level has 
been mentioned previously. Since lipolysis in adipocytes and glucose production in 
hepatocytes are inhibited by insulin and since glucose uptake in muscles is triggered, 
diminished insulin secretion due to β-cell dysfunction results in increased free fatty acid 
production and in a rise of blood glucose concentration (reviewed in Stumvoll et al., 2005). 
The increased concentrations of fatty acids and glucose in turn affect insulin sensitivity and 
secretion negatively (reviewed in Chang-Chen et al., 2008). Thus deterioration of insulin 
homeostasis marks the onset of a vicious cycle, eventually leading to T2DM. 
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The two main candidates causing β-cell dysfunction are glucotoxicity and lipotoxicity 
(reviewed in Chang-Chen et al., 2008), but the normal pathway triggering insulin secretion is 
presented previous to describing the cellular mechanism behind these concepts. The signal 
for β-cells to release preformed insulin is incoming glucose. The ATP formed from the 
metabolism of glucose through glycolysis and oxidative phosphorylation serves as fuel for the 
insulin exocytosis. Additionally the consequently increased ATP/ADP ratio induces a 
depolarization of the membrane through closing potassium channels (reviewed in Stumvoll et 
al., 2005). This leads to an opening of calcium channels and a subsequent increase in calcium 
concentration, which is necessary for the exocytosis (reviewed in Stumvoll et al., 2005).  
The more recent theory of lipotoxicity is based on three effects of the increased uptake of free 
fatty acids by β-cells (reviewed in Stumvoll et al., 2005). First, the accumulation of long-chain 
acyl coenzyme A might decrease insulin release through opening potassium channels. Second, 
protein synthesis of uncoupling protein 2 might be activated, leading to uncoupling of the 
electron transport chain and ATP synthases in mitochondria and hence decreased ATP 
formation. The third possible effect is induction of apoptosis. It is still not sure which 
contribution lipotoxicity has to impaired insulin secretion, but it is suggested that the free 
fatty acids primarily have an effect when accompanied by glucotoxicity (reviewed in Chang-
Chen et al., 2008). Glucose toxicity is characterized by the increased formation of reactive 
oxygen species due to high blood glucose concentrations and hence a higher rate of 
metabolism. This may lead to irreparable cellular damage and apoptosis (reviewed in 
Stumvoll et al., 2005). 
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8.2 GFP-transfection of INS-1E cells 
The experiment is designed to determine optimal amount of lipofectamine2000 and DNA for 
use in a transfection assay to achieve the highest transfection efficiency. This is done by 
transfecting with a plasmid containing a gene coding for GFP, thereby creating a quantitative 
measure of transfection efficiency according to the expression of the GFP protein.  
Lipofectamine 2000 (LF2000) is a cationic liposome derived agent, which during incubation 
with DNA forms micelles and can fuse with the INS-1E membrane. Optimem, a cationic 
liposome compatible reduced serum media, is used for the transfection. 
The experiment was conducted with two variables. In some samples the DNA concentrations 
were varied and the LF2000 were held constant. In other samples LF2000 concentrations 
were varied while the DNA concentrations were held constant. The efficiency of the 
experiment is determined from an analysis of the number of cells transfected with GFP, 
detected with a fluorescence microscope. 
8.2.1 Method 
INS-E1 cells were cultured as written in section  2.2 The cells were grown in 12 well plates. 
Varied amount of GFP 
The amount of DNA per well were varied, testing for the highest transfection efficiency. Four 
samples were made containing 0.8, 1.6, 3.2 or 6.4 µg of the GFP-vector per well, named DNA-
samples. A control sample was made, where water was used instead of DNA. 80 µl 
optimem/well was added to DNA-samples and water was added to a total volume of 92.8 
µl/well. A LF2000-mastermix for a fixed amount LF2000 were made by mixing of 1.6 µl 
LF2000 pr well with 80 µl optimem. This mix was then incubated for 5 min at RT. The DNA-
samples were mixed with the LF2000-mastermix and incubated for 20 min at RT. 
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Varied amount of LF2000 
Varying the amount of LF2000, 0.9; 1.8; 3.6; 7.2 µl was used per well. A control was made with 
water instead of LF2000. LF2000-samples were made by mixing 180 µl optimem, the varied 
concentration of LF2000. Water was added to a total amount of 92.7 µl per well.  
A DNA-Mastermix was made; containing 1.8 µg GFP per well and 90 µl optimem per well with 
a 5 min incubation time at RT. The DNA-mastermix and LF2000 samples were mixed and 
incubated for 20 min at RT. 190 µl of the mixes were added to the wells, which then were 
incubated for 48 hours. 
8.2.2 Results  
After 48 hours of transfection the cells were analysed with fluorescence microscopy and 
compared with the amount of cells seen under normal light. Figure A1-A10 shows a 
representative sample from each transfection, with both normal and UV light exposure. Figure 
A1-A5 are results from the varied GFP amount and figure A6-A10 are results from the varied 
LF2000 amount. 
Comparing results from the fixed-LF2000 experiment, it is seen that fluorescence activity on 
figure A2 and A3 are higher than on figure A1 and A4, while the negative control on Figure A5 
shows no fluorescence activity. It is not as easy to distinguish the level of fluorescence 
between Figure A2 and A3. Comparing the amount of cells transfected and Non-transfected in 
both figures, no significant difference can be established. IT can be hypothesized that the 
optimum value is somewhere between the two values tested, 1.6 µg and 3.2 µg pr well in a 12 
well plate. When comparing activity of the fixed-DNA experiments, it seems clear that Figure 
A7 shows the highest amount of fluorescence compared with the others. That transfection 
was performed with 1.8 µl LF2000. The ratio between transfected and non-transfected cells 
also seem to be highest in Figure A7, giving the highest transfection efficiency. The 
experiment was sufficient to determine an approximate optimal relationship between LF-
2000 and DNA for transfections in INS-1E cells. When the LF-2000 level was kept constant at 
1.8 µg pr well, the best transfection efficiency was obtained by using somewhere between 1.6 
µg and 3.2 µg pr 12 plate well. When the DNA was kept constant at 1.8 µg pr well the best 
transfection efficiency was obtained by using 1.8 µg LF-2000. These data correlates to each 
other and suggests that optimal values is about 2 µg DNA and 2 µg LF-2000 pr 12 well.  
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Figure: A1: The results of GFP transfection 
with 0,8 µg GFP and 1,6 µL LF2000 are seen  
under the fluorscence microscopy 
Figure A2 - The results of GFP transfection 
with 1,6 µg GFP and 1,6 µL LF2000 are seen  
under the fluorscence microscopy. 
Figure A3: The results of GFP transfection with 
3.2 µg GFP and 1 .6 µl LF2000 are seen under the 
fluorscence microscopy. 
Figure A4: The results of GFP transfection with 6.4 µg 
GFP and 1.6 µL LF2000 are seen under the 
fluorscence microscopy. 
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Figure A5: The results of GFP transfection without GFP 
and 1.6 µl LF2000 are seen under the fluorescence 
microscopy. 
Figure A6, The results of GFP transfection with 0.9 
µL LF2000 and 1.8 µg GFP are seen under the 
fluorescence microscopy. The green lightning spots 
indicates cells successfully transfected                         
Figure A7: The results of GFP transfection with 1.8 
µL LF2000 and 1.8 µg GFP are seen under the 
fluorescence microscopy. The green lightning spots 
indicates cells successfully transfected  
Figure A8 - The results of GFP transfection with 3.6
µL LF2000 and 1.8 µg GFP are seen under the 
fluorescence microscopy. The green lightning spots 
indicates cells successfully transfected. 
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Figure A9: The results of GFP transfection with 7.2 
µL LF2000 and 1.8 µg GFP are seen under the 
fluorescence microscopy. The green lightning spots 
indicates cells successfully transfected 
Figure A10: The results of GFP transfection without 
LF2000 and 1.8 µg GFP are seen under the 
fluorescence microscopy and no fluorescence light 
are seen. 
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8.4 Statistical Test 
pGL4.13 as well as Perf are not considered in the statistical analysis, as the results for these 
samples are clearly different from Stx1a. The data is considered normal distributed as they 
are measurements of luciferase activity. The variance is analyzed with an F-test. The F-test 
ensures that the variances of two datasets do not differ from each other significantly. If the 
probability (p) is more than 5 %, the hypothesis of equal variances cannot be rejected. If p > 
0.05, data can be analyzed with a normal t-test. If p ≤ 0.05, another t-test has to be applied. As 
seen in Figure 14, the hypothesis of equal variances can only be rejected, when comparing the 
results of the Stx1a- and Mut2-constructs in the 20 mM glucose transfection. Since the 
variance of Stx1a in the 20 mM glucose assay is in the normal range compared to the other 
standard variations in the experiment, the finding of unequal variances is likely due to the 
coincidence that the measurements of Mut2 are almost alike, giving a very low standard 
variation. 
The t-test used is performed in Excel 07. Excel contains three different t-tests; a paired test, an 
unpaired equal variance test, and an unpaired unequal variance test. All data are unpaired and 
hence the t-test is bidirectional. The equal variance test is used for all data analysis, except 
when comparing Stx1a and Mut2 with an unequal variance test. The t-test evaluates the 
difference between the mean-values of the replicates of one sample. The p-values from the t-
test are shown in Figure 14, where scores of p < 0.05 are marked green and the evaluated 
hypothesis of different mean values cannot be rejected. 
The statistical analysis reveals that in some cases the downregulation of FF expression in 
Stx1a-plasmid is significant compared to the negative controls, Mut2 and Scr, and in others it 
is not. In the data material analyzed here, the mean values of one sample are often only 
obtained from two replicates, which make it possible that there is a considerable standard 
error. Therefore it is possible that unambiguous results would have been obtained, if the test 
had been replicated and carried out in quadruplicates 
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5mM glucose 11mM glucose 20mM glucose 
Plasmids F-test t-test F-test t-test F-test t-test 
Stx1a & Scr 0,526 0,033 0,266 0,360 0,776 0,038 
Stx1a & Mut2 0,955 0,020 0,213 0,018 0,037 0,113 
Mut2 & Scr 0,331 0,152 0,903 0,028 0,053 0,546 
Table 1: P-values from F-tests and t-tests calculated with excel. To determine, whether the measured average 
ratios obtained from the transfections with Stx1a-, Scr- and Mut2-constructs, differ significantly from each 
other, a t-test is used. A condition for using a t-test is equal variances of the data, which is tested by the F-test. 
The green fields mark the t-tests, where the mean values evaluated are significantly different. 
 
